Irritable bowel syndrome following COVID-19: an underestimated consequence of SARS-CoV-2 infection.
Pol Arch Intern Med
; 132(11)2022 11 25.
Article
in English
| MEDLINE | ID: covidwho-2002740
ABSTRACT
INTRODUCTION:
Gastrointestinal (GI) symptoms are a common manifestation of COVID19.OBJECTIVES:
We aimed to investigate whether GI symptoms persist in patients previously infected with SARSCoV2 in the form of postinfection irritable bowel syndrome (PIIBS). PATIENTS ANDMETHODS:
A prospective, singlecenter evaluation of questions regarding IBS was conducted using the Rome IV Adult Diagnostic Questionnaire among 257 patients previously hospitalized for COVID19.RESULTS:
GI symptoms (abdominal pain with diarrhea or constipation) were reported at the following time points at discharge from the hospital, and after 3 and 6 months of followup. GI symptoms not meeting the full Rome IV diagnostic criteria for IBS due to too short symptom duration were reported by 28 individuals (10.6%) at hospital discharge, 58 (22.3%) after 3 months, and 70 (26.9%) after 6 months. The full Rome IV criteria for IBS were not met at discharge by any of the participants, but they were met after 3 and 6 months of followup in 14 (5.4%) and 15 individuals (5.8%), respectively.CONCLUSION:
Persistent GI symptoms following COVID19 are frequent and deserve significant and growing attention of gastroenterologists and other health care practitioners. The Rome IV criteria may be too strict to address the full spectrum of GI symptoms following COVID19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Irritable Bowel Syndrome
/
Gastrointestinal Diseases
/
COVID-19
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Adult
/
Humans
Language:
English
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS